GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bydureon BCise

Company
Vivani Medical, Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Bydureon BCise and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05356104

    GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

    Not yet reported Chinese University of Hong Kong 110 participants Est. completion 2027-12 2 sites
    Other conditions: Cerebral Small Vessel Disease
    View official trial listing →
  • Recruiting NCT NCT05663515

    A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

    AstraZeneca 24000 participants Est. completion 2026-10-01 8 sites
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT03970044

    Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

    Not yet reported Consano Clinical Research, LLC 67 participants Est. completion 2021-06-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05670379

    Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

    Not yet reported Vivani Medical, Inc 24 participants Est. completion 2025-08-21 1 site
    Other conditions: Overweight and Obesity, Type2diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Bydureon BCise, Bydureon BCise (exenatide extended release)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.